Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Maria-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses a phase 2 study evaluating single-agent daratumumab activity in patients with heavily pretreated refractory multiple myeloma.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.